Repligen Corporation logo

Repligen Corporation

RGEN

NASDAQHealthcareMedical - Instruments & Supplies

Previous close

$181.13

+$0.84 · +0.47%

Aug 21, 4:00 PM ET

RGEN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

16

Overpriced

Momentum

47

Neutral

Sentiment

67

Bullish

Risk resilience

54

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
Olivier Loeillot
Listed since
Apr 29, 1986
Employees
2,000

Market position

Day range

Current $181.13

52-week range

Current $181.13

Open
$179.21
Previous close
$180.29
Volume
1.1M
0.93× average
Average volume
1.18M
Average daily volume
Market cap
10.22B USD
Beta
1.01
Market reference 1
50-day average
$146.95
+23.26% above average
200-day average
$140.61
+28.82% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
9.34B USD
P/E (TTM)
244.77×
P/B (TTM)
4.84×
P/S (TTM)
13.02×
EV / EBITDA
56.84×
Earnings yield
0.53%
Free cash flow yield
1.02%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
51.05%
Operating margin
8.32%
Net margin
5.29%
Return on equity
2.32%
Return on assets
1.66%
Return on invested capital
1.65%

Financial health

Debt / equity
0.33×
Current ratio
8.37×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends65%39%14%-12%Gross margin, FY2021: 58.35%Gross margin, FY2022: 56.85%Gross margin, FY2023: 44.03%Gross margin, FY2024: 43.29%Gross margin, FY2025: 47.09%Operating margin, FY2021: 24.94%Operating margin, FY2022: 28.03%Operating margin, FY2023: 7.54%Operating margin, FY2024: -5.53%Operating margin, FY2025: 8.07%Net margin, FY2021: 19.13%Net margin, FY2022: 23.20%Net margin, FY2023: 5.63%Net margin, FY2024: -4.02%Net margin, FY2025: 6.62%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 58.35%. Gross margin FY2022 56.85%. Gross margin FY2023 44.03%. Gross margin FY2024 43.29%. Gross margin FY2025 47.09%. Operating margin FY2021 24.94%. Operating margin FY2022 28.03%. Operating margin FY2023 7.54%. Operating margin FY2024 -5.53%. Operating margin FY2025 8.07%. Net margin FY2021 19.13%. Net margin FY2022 23.20%. Net margin FY2023 5.63%. Net margin FY2024 -4.02%. Net margin FY2025 6.62%.

Income trends

Revenue

738.26M USD+16.36%

Operating income

59.58M USD+94.69M USD

Net income

48.89M USD+74.41M USD
Income trends across reported periods885.2M USD550.54M USD215.88M USD−118.78M USDRevenue, FY2021: 670.53M USDRevenue, FY2022: 801.54M USDRevenue, FY2023: 632.36M USDRevenue, FY2024: 634.44M USDRevenue, FY2025: 738.26M USDOperating income, FY2021: 167.25M USDOperating income, FY2022: 224.67M USDOperating income, FY2023: 47.7M USDOperating income, FY2024: −35.11M USDOperating income, FY2025: 59.58M USDNet income, FY2021: 128.29M USDNet income, FY2022: 185.96M USDNet income, FY2023: 35.6M USDNet income, FY2024: −25.51M USDNet income, FY2025: 48.89M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 670.53M USD. Revenue FY2022 801.54M USD. Revenue FY2023 632.36M USD. Revenue FY2024 634.44M USD. Revenue FY2025 738.26M USD. Operating income FY2021 167.25M USD. Operating income FY2022 224.67M USD. Operating income FY2023 47.7M USD. Operating income FY2024 −35.11M USD. Operating income FY2025 59.58M USD. Net income FY2021 128.29M USD. Net income FY2022 185.96M USD. Net income FY2023 35.6M USD. Net income FY2024 −25.51M USD. Net income FY2025 48.89M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue738.26M USD634.44M USD632.36M USD801.54M USD670.53M USD
Cost of goods sold390.63M USD359.79M USD353.92M USD345.83M USD279.28M USD
Gross profit347.62M USD274.65M USD278.44M USD455.71M USD391.25M USD
Research and development54.18M USD43.2M USD42.72M USD43.94M USD34.27M USD
Selling, general, and administrative290.51M USD263.37M USD218.58M USD215.83M USD183.87M USD
Operating expenses288.05M USD309.76M USD230.74M USD231.04M USD224.01M USD
Interest income27.57M USD6.98M USD176K USD
Interest expense23.17M USD22.57M USD10.03M USD2.98M USD12.71M USD
Depreciation and amortization78.75M USD86.56M USD86.11M USD57.01M USD38.45M USD
Operating income59.58M USD−35.11M USD47.7M USD224.67M USD167.25M USD
Net income48.89M USD−25.51M USD35.6M USD185.96M USD128.29M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 3 misses, 1 met estimate
Average EPS surprise
+9.19%
11 comparable reports
Latest EPS result
0.54
Estimate 0.45 · Beat by 20.81%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.580.490.40.31Q1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 20, 2025: actual 0.44, estimate 0.41, surprise +7.32%, Beat. Q2 2025, reported Apr 29, 2025: actual 0.39, estimate 0.35, surprise +11.43%, Beat. Q3 2025, reported Jul 29, 2025: actual 0.37, estimate 0.4, surprise -7.50%, Miss. Q4 2025, reported Oct 28, 2025: actual 0.46, estimate 0.42, surprise +9.52%, Beat. Q1 2026, reported Feb 24, 2026: actual 0.49, estimate 0.44, surprise +11.36%, Beat. Q2 2026, reported May 5, 2026: actual 0.48, estimate 0.38, surprise +26.32%, Beat. Q3 2026, reported Jul 28, 2026: actual 0.54, estimate 0.447, surprise +20.81%, Beat. Q4 2026, reported Oct 27, 2026: actual —, estimate 0.46, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates215.07M195.18M175.3M155.42MQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 20, 2025: actual 167.55M USD, estimate 167.65M USD, surprise -0.06%, Miss. Q2 2025, reported Apr 29, 2025: actual 169.17M USD, estimate 163.69M USD, surprise +3.35%, Beat. Q3 2025, reported Jul 29, 2025: actual 182.37M USD, estimate 175.18M USD, surprise +4.10%, Beat. Q4 2025, reported Oct 28, 2025: actual 188.81M USD, estimate 182.13M USD, surprise +3.67%, Beat. Q1 2026, reported Feb 24, 2026: actual 197.91M USD, estimate 192.94M USD, surprise +2.58%, Beat. Q2 2026, reported May 5, 2026: actual 194.26M USD, estimate 192.05M USD, surprise +1.15%, Beat. Q3 2026, reported Jul 28, 2026: actual 204.13M USD, estimate 201.59M USD, surprise +1.26%, Beat. Q4 2026, reported Oct 27, 2026: actual —, estimate 206.8M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$152

16.08% downside
Past 12 months12-month forecastHigh $160Average $152Low $142

Rating distribution

24 ratings
Strong buy14%
Buy2188%
Hold28%
Sell00%
Strong sell00%

RGEN news

RGEN peers

ETFs holding RGEN

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research RGEN

research.disclaimer